Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
- 20 March 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , 852-856
Abstract
We evaluated low-dose infliximab (5 mg/kg) as adjunctive therapy in 20 patients with severe central nervous system tuberculosis. At 3 months, 60% achieved disability-free survival (modified Rankin Scale ≤ 2), and 75% showed clinically meaningful improvement. Our outcomes matched reports of high-dose infliximab. Randomized trials to optimize dosing are needed.Keywords
This publication has 14 references indexed in Scilit:
- Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort StudyClinical Infectious Diseases, 2023
- Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitisClinical Microbiology and Infection, 2023
- The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: a case series and literature reviewEuropean Journal of Clinical Microbiology & Infectious Diseases, 2023
- Tuberculous meningitis: a uniform case definition for use in clinical researchThe Lancet Infectious Diseases, 2010
- Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph NodesClinical Infectious Diseases, 2008
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Tumor Necrosis Factor and TuberculosisJournal of Investigative Dermatology Symposium Proceedings, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Reconsidering Adjuvant Immunotherapy for TuberculosisClinical Infectious Diseases, 2005
- The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002